Ultra-low-dose Chest CT for HHT

N/AActive Not RecruitingNCT04874558

Mayo Clinic10 enrolled

Overview

This study aims to develop a novel ultra-low dose chest CT technology for use in Hereditary Hemorrhagic Teleangiectasia (HHT) patients and to determine the lowest possible radiation dose that is achievable without sacrificing the diagnostic quality.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hereditary Hemorrhagic Telangiectasia

Interventions

Ultra-low dose chest CTDIAGNOSTIC_TEST

A novel CT technique with a new dose optimization and efficiency technology and automatic kV selection, which greatly reduces the dose of radiation exposure compared to a standard chest CT.

Eligibility

Sex: ALLMin age: 1 YearMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Ages 1 to 17 years * Diagnosed with positive HHT causing mutations or based on Curacao criteria Exclusion Criteria: * Acute respiratory distress * Unstable cardiovascular status * Pneumothorax, hemoptysis * Pulmonary edema * Pulmonary emboli * Fractured ribs or other chest trauma * Recent bronchoscopy * Lung transplantation

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Ultra-low dose images PAVM detection

Number of images detecting PAVM using the ultra-low dose images (50% or lower compared to the full dose)

Time frame: Baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.